PLIANT THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
PLIANT THERAPEUTICS, INC. (PLRX) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$781.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $943.00K.
- PLIANT THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$1.72M.
- PLIANT THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $209.00K, a 79.55% decline year-over-year.
- PLIANT THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$780.00K.
- PLIANT THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$2.54M.
- PLIANT THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$4.72M, a 226.29% decline from fiscal 2023.
- PLIANT THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $3.73M, a 1170.41% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $294.00K, a 87.03% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $943.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$781.00K 10-Q · filed 2026-08-11 | -$572.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.35M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$1.72M 10-Q · filed 2026-05-11 | -$1.51M derived: sum of 2 quarters · filed 2026-05-11 | -$2.29M derived: sum of 3 quarters · filed 2026-05-11 | -$3.27M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $209.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$571.00K derived: sum of 2 quarters · filed 2026-03-11 | -$1.55M derived: sum of 3 quarters · filed 2026-08-11 | -$2.54M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$780.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.75M derived: sum of 2 quarters · filed 2026-08-11 | -$2.75M 10-Q · filed 2025-11-06 | -$1.73M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$975.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.97M 10-Q · filed 2026-08-11 | -$948.00K derived: sum of 3 quarters · filed 2026-08-11 | -$6.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$995.00K 10-Q · filed 2026-05-11 | $27.00K derived: sum of 2 quarters · filed 2026-05-11 | -$5.40M derived: sum of 3 quarters · filed 2026-05-11 | -$1.96M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$4.40M derived: sum of 2 quarters · filed 2026-03-11 | -$968.00K derived: sum of 3 quarters · filed 2026-03-11 | -$4.72M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$5.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.99M derived: sum of 2 quarters · filed 2025-11-06 | -$5.74M 10-Q · filed 2025-11-06 | -$5.59M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$313.00K 10-Q · filed 2025-08-07 | -$161.00K derived: sum of 3 quarters · filed 2025-08-07 | $1.61M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$3.75M 10-Q · filed 2025-05-08 | -$3.60M derived: sum of 2 quarters · filed 2025-05-08 | -$1.82M derived: sum of 3 quarters · filed 2025-05-08 | -$490.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $152.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.93M derived: sum of 2 quarters · filed 2025-03-03 | $3.26M derived: sum of 3 quarters · filed 2025-03-03 | $3.73M 10-K · filed 2025-03-03 |
| 2023-09-30 | $1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.11M derived: sum of 2 quarters · filed 2024-11-07 | $3.58M 10-Q · filed 2024-11-07 | $6.48M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.81M 10-Q · filed 2024-08-07 | $4.71M derived: sum of 3 quarters · filed 2025-03-03 | $4.01M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $476.00K 10-Q · filed 2024-05-06 | $3.38M derived: sum of 2 quarters · filed 2025-03-03 | $2.68M derived: sum of 3 quarters · filed 2025-03-03 | $1.78M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $2.20M derived: sum of 2 quarters · filed 2025-03-03 | $1.31M derived: sum of 3 quarters · filed 2025-03-03 | $294.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | -$698.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.59M derived: sum of 2 quarters · filed 2023-11-09 | -$2.60M 10-Q · filed 2023-11-09 | -$1.24M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$894.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.91M 10-Q · filed 2023-08-09 | -$541.00K derived: sum of 3 quarters · filed 2024-02-27 | $31.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$1.01M 10-Q · filed 2023-05-09 | $353.00K derived: sum of 2 quarters · filed 2024-02-27 | $925.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.57M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.94M derived: sum of 2 quarters · filed 2024-02-27 | $2.58M derived: sum of 3 quarters · filed 2024-02-27 | $2.27M 10-K · filed 2024-02-27 |
| 2021-09-30 | $572.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.22M derived: sum of 2 quarters · filed 2022-11-08 | $900.00K 10-Q · filed 2022-11-08 | -$1.12M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $646.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $328.00K 10-Q · filed 2022-08-08 | -$1.69M derived: sum of 3 quarters · filed 2022-08-08 | -$3.35M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$318.00K 10-Q · filed 2022-05-09 | -$2.34M derived: sum of 2 quarters · filed 2022-05-09 | -$3.99M derived: sum of 3 quarters · filed 2022-05-09 | $1.55M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$3.67M derived: sum of 2 quarters · filed 2022-03-01 | $1.87M derived: sum of 3 quarters · filed 2022-03-01 | $2.76M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $3.89M derived: sum of 2 quarters · filed 2021-11-09 | $4.77M 10-Q · filed 2021-11-09 | $4.91M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $5.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $6.43M 10-Q · filed 2021-08-09 | $6.57M derived: sum of 3 quarters · filed 2022-03-01 | $7.69M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $883.00K 10-Q · filed 2021-05-10 | $1.02M derived: sum of 2 quarters · filed 2022-03-01 | $2.15M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.26M derived: sum of 2 quarters · filed 2022-03-01 | $1.46M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $1.32M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $196.00K 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |